PACTR202206754734018尚未招募3 期
Safety & Immunogenicity of Fractional Doses of Pfizer, AstraZeneca, and Janssen Covid-19 Vaccines Among Nigerian Adults- A Randomised Non-Inferiority Triple Blind Trial
igeria Federal Ministry of health0 个研究点目标入组 1,812 人开始时间: 2022年1月14日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 1,812
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •Healthy based on medical examination/history at the inclusion
- •Age 18-65 years
- •Signed informed consent
- •Prepared to grant authorized persons access to the medical records
- •The volunteer is likely to comply with instructions
- •Non pregnant female above 18 years
排除标准
- •On current treatment with investigational agents for prophylaxis of COVID-19.
- •Plan to travel outside Nigeria from enrolment through 28 days after the last vaccination
- •Participation in other clinical trials
- •Known hypersensitivity to any of the vaccine components
- •History of hypersensitivity or severe allergic reaction
- •Laboratory parameters outside of normal range considered clinically relevant
- •Pregnant woman
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses IntramuscularlyPoliomyelitisEUCTR2015-005183-42-Outside-EU/EEASanofi Pasteur SA236
已完成
不适用
Immune response of fractional doses of Inactivated Poliovirus Vaccine (IPV) administered intradermally in the Sultanate of OmaPoliomyelitis vaccinationInfections and InfestationsPoliomyelitisISRCTN17418767World Health Organization (WHO) (Switzerland)400
进行中（未招募）
不适用
Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose IntramuscularlyPoliomyelitisEUCTR2015-005184-16-Outside-EU/EEASanofi Pasteur SA225
已完成
不适用
Evaluation of a prototype vaccine against enterotoxigenic Escherichia coli diarrhoeaEnterotoxigenic E. coli (ETEC) diarrhoeaInfections and InfestationsEnterotoxigenic Escherichia coli infectionISRCTN23764070Gothenburg University Vaccine Research Institute (GUVAX) (Sweden)60
进行中（未招募）
1 期
Safety and immunological response against SARS-CoV-2 after revaccination with mRNA-1273 with a ceramic skin patchSafety and immunogenicity after revaccination with Spikevax in healthy adults who have received Comirnaty as a primary vaccineEUCTR2021-006754-31-NLeiden University Medical Center20